

## P R E S S R E L E A S E

Lyon, September 21<sup>st</sup>, 2020

---



**ADOCIA**

innovative medicine  
for everyone, everywhere

# Adocia announces a Video Conference to Present a Corporate Update Wednesday, September 23<sup>rd</sup>, 2020

6:30 PM CET - ADOCIA (Euronext Paris: FR0011184241 – ADOC, the “Company”), the biopharmaceutical company focused on the treatment of diabetes and other metabolic diseases with innovative formulations of proteins and peptides, announced that Adocia's management will present a review of its activities over the last few months and will discuss the recent clinical results obtained on the M1Pram product.

The presentation will be in French, based on an online presentation and will not include a question/answer session.

### Presentation details:

#### Presenters:

- Gérard Soula, President and CEO
- Olivier Soula, Deputy General Manager and R&D Director
- Valérie Danaguezian, Financial Director

**Presentation Day:** Wednesday September 23<sup>rd</sup>, 2020

**Time:** 6:30 PM (CET)

### To attend Zoom Conference

<https://zoom.us/j/98158535153?pwd=NS95djZlbnBFYlY1RzQ1Vk9ma1lydz09>

ID meeting : 981 5853 5153

Pin Code : bnK8nQ

## About Adocia

Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of therapeutic proteins and peptides for the treatment of diabetes and metabolic diseases. In the diabetes field, Adocia's portfolio of injectable treatments is among the largest and most differentiated of the industry, featuring four clinical-stage products. Adocia aims to expand its portfolio towards the treatment of other metabolic diseases and their comorbidities. The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. Adocia customizes BioChaperone to each protein for a given application.

Adocia's clinical pipeline includes four novel insulin formulations for prandial treatment of diabetes: two ultra-rapid formulations of insulin analog lispro (BioChaperone® Lispro U100 and U200), a combination of basal insulin glargine and rapid-acting insulin lispro (BioChaperone® Combo) and one combination of a prandial insulin with amylin analog pramlintide M1Pram (ADO09). The clinical pipeline also includes an aqueous formulation of human glucagon (BioChaperone® Glucagon) for the treatment of hypoglycemia.

Adocia preclinical pipeline includes three products: a combination of rapid human insulin analogues and Pramlintide (BioChaperone LisPram), a combination of insulin glargine with GLP-1 receptor agonists (BioChaperone® Glargine GLP-1) for the treatment of diabetes and a ready-to-use combination of glucagon and a GLP-1 receptor agonist (BioChaperone® Glucagon GLP1) for the treatment of obesity.

## Contact Adocia

### Adocia

**Gérard Soula**

CEO

contactinvestisseurs@adocia.com

Ph: +33 4 72 610 610

[www.adocia.com](http://www.adocia.com)

### MC Services AG

Adocia Press Relations Europe

**Raimund Gabriel**

Managing Partner

adocia@mc-services.eu

Ph: +49 89 210 228 0

### The Ruth Group

Adocia Investor Relations USA

**James Salierno**

Vice-President

jsalierno@theruthgroup.com

Ph: +1 646 536 7035



European **Rising Tech**  
LABEL



**ADOCIA**

innovative medicine  
for everyone, everywhere



## Disclaimer

*This press release contains certain forward-looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the "Risk Factors" section of the Reference Document filed with the French Autorité des marchés financiers on April 22, 2020 (a copy of which is available at [www.adocia.com](http://www.adocia.com)) and to the development of economic condi-*

*tions financial markets and the markets in which Adocia operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not currently considered material by Adocia. The occurrence of all or part of such risks could cause actual results, financial conditions, performance, or achievements of Adocia to be materially different from such forward-looking statements.*

*This press release and the information contained herein do not constitute an offer to sell or the solicitation of an offer to buy Adocia shares in any jurisdiction.*